Name | Pasireotide Acetate |
Description | Pasireotide (SOM230) acetate is a long-acting cyclohexapeptide growth hormone inhibitory hormone analog with antisecretory, antiproliferative, and proapoptotic activities.Pasireotide (SOM230) acetate inhibits the secretion of GH, IGF-I, and ACTH, and can be used in the study of acromegaly and Cushing's disease. Pasireotide (SOM230) acetate also enhances the agonist activity of growth inhibitory receptors, with pKi of 8.2, 9.0, 9.1, <7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively. |
In vitro | Pasireotide (SOM230) acetate enhances agonist activity at growth inhibitory receptors with pKi of 8.2, 9.0, 9.1, less than 7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively. |
In vivo | METHODS: Pasireotide (SOM230) acetate (160 mg/kg, subcutaneous injection, four months) was administered to a MEN1 transgenic mouse model, and the effects of Pasireotide (SOM230) acetate on insulin secretion, glucose levels, tumor growth and survival were tested.
RESULTS Pasireotide (SOM230) acetate significantly decreased serum insulin, increased serum glucose, decreased tumor size and increased Pdx1-Cre cell apoptosis. [1] |
Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 50 mg/mL (45.16 mM), Sonication is recommended.
|
Keywords | Somatostatin Receptor | sst3 | Inhibitor | SOM230 | SOM 230 | Pasireotide | proapoptotic | sst1 | antiproliferative | inhibit | somatostatin | SSTRs | sst4 | SOM-230 | SSTR | sst5 | antisecretory | Pasireotide Acetate | sst2 |
Inhibitors Related | 2-Aminoethanethiol | Somatostatin acetate |
Related Compound Libraries | Cyclic Peptide Library | Bioactive Compound Library | Peptide Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |